ArticleCell biochemistry and biophysics2026
Green Tea-Driven Green Synthesis of a Curcumin@Platinum Nanohybrid with Multifunctional Antioxidant, Burn-Healing Agent, and Selective Anticancer against PANC-1 Pancreatic Cancer Cells.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ROS and Antioxidants: Prospective Therapeutic Options in Cancer.Journal of cellular and molecular medicine · 2026Article
- Green Synthesis of Iron Oxide-Chitosan-Glutathione Nanosystem for Wound Healing Enhancement.Cell biochemistry and biophysics · 2026Article
- Green Synthesis of Iron Oxide-Chitosan-Glutathione Nanosystem for Wound Healing Enhancement.Cell biochemistry and biophysics · 2026Article
- Green Tea-Driven Green Synthesis of a Curcumin@Platinum Nanohybrid with Multifunctional Antioxidant, Burn-Healing Agent, and Selective Anticancer against PANC-1 Pancreatic Cancer Cells.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to fabricate a curcumin@platinum nanohybrid (CUR@Pt NPs) through a green tea–based synthesis method and to evaluate its various functions, including antioxidant, burn-healing, and selective anticancer activities against PANC-1 pancreatic cancer cells. Green tea polyphenols served as natural reducing and stabilizing agents, facilitating an eco-friendly, single-step manufacturing process. Physicochemical characterization confirmed successful nanohybrid formation: a CUR@Pt band appeared at 457 nm in the UV–Vis spectrum, XRD displayed crystalline platinum peaks at 2θ = 46.9°, and 67.0°, matching the (200), and (220) planes, respectively, and TEM images showed well-dispersed spherical nanoparticles with an average size of 50 nm. FTIR spectra showed shifts in O–H and C = O vibrational bands, indicating coordination between curcumin, tea polyphenols, and platinum. DLS analysis indicated a hydrodynamic diameter of 162.2 ± 12.8 nm, with a zeta potential of − 5.6 mV. Antioxidant assessment using the DPPH assay revealed that CUR@Pt NPs had enhanced radical-scavenging activity with an IC₅₀ of 17.58 ppm, compared to 22.45 ppm for free curcumin. In vivo burn-healing tests in mice demonstrated faster wound contraction, with the CUR@Pt group achieving significantly improved closure by day 14, along with increased re-epithelialization and dense collagen deposition similar to silver sulfadiazine (1%). Cytotoxicity assays showed selective anticancer effects against PANC-1 cells (IC₅₀ = 89.4 µg/mL), while normal NIH cells displayed higher tolerance (IC₅₀ = 119.8 µg/mL), indicating a favorable therapeutic index. In conclusion, CUR@Pt NPs are a promising, environmentally friendly nanoplatform that combines the complementary pharmacological effects of curcumin and platinum.
Indexed as
Identifiers
41369704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.